With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx

 
• By Joseph Haas

While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.

Exelixis needs new strategy
Exelixis needs a new strategy in first-line liver cancer after Phase III miss • Source: Alamy

More from Clinical Trials

More from R&D